Cargando…

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers in non-small-cell lung cancer (NSCLC). Significant developments have taken place which highlight the differences in tumor biology that exist between the mutant and wild-type subtypes of NSCLC. Patients with advan...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Leary, Connor, Gasper, Harry, Sahin, Katherine B., Tang, Ming, Kulasinghe, Arutha, Adams, Mark N., Richard, Derek J., O’Byrne, Ken J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600164/ https://www.ncbi.nlm.nih.gov/pubmed/32992872 http://dx.doi.org/10.3390/ph13100273

Ejemplares similares

High-Plex and High-Throughput Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC)
por: Monkman, James, et al.
Publicado: (2020)

The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells
por: Kulasinghe, Arutha, et al.
Publicado: (2020)

Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC)
por: Kulasinghe, Arutha, et al.
Publicado: (2022)

Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel
por: Zhou, Jian, et al.
Publicado: (2019)

Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer
por: Kapeleris, Joanna, et al.
Publicado: (2020)

Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer
por: O’Leary, Connor, et al.
Publicado: (2019)

Pembrolizumab-induced toxic epidermal necrolysis: case report
por: Chow, Kar Ven Cavan, et al.
Publicado: (2022)

Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients
por: Kulasinghe, Arutha, et al.
Publicado: (2021)

The Role of Circulating Biomarkers in Lung Cancer
por: Herath, Sayuri, et al.
Publicado: (2022)

Understanding the tumor microenvironment for effective immunotherapy
por: Sadeghi Rad, Habib, et al.
Publicado: (2020)

Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets
por: Kulasinghe, Arutha, et al.
Publicado: (2019)

The evolving landscape of predictive biomarkers in immuno‐oncology with a focus on spatial technologies
por: Sadeghi Rad, Habib, et al.
Publicado: (2020)

Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas
por: Sadeghirad, Habib, et al.
Publicado: (2022)

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
por: Kapeleris, Joanna, et al.
Publicado: (2022)

The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer
por: Kulasinghe, Arutha, et al.
Publicado: (2018)

The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
por: Kapeleris, Joanna, et al.
Publicado: (2018)

Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab
por: Rajapakse, Aleksandra, et al.
Publicado: (2020)

Epidermal growth factor receptor mutated oligometastatic adeno-squamous lung cancer transformation to small cell lung cancer
por: O’Leary, Connor G, et al.
Publicado: (2018)

Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review
por: Fernandez, Alejandra, et al.
Publicado: (2021)

Understanding the tumor microenvironment in head and neck squamous cell carcinoma
por: Rad, Habib Sadeghi, et al.
Publicado: (2022)

Enrichment of circulating head and neck tumour cells using spiral microfluidic technology
por: Kulasinghe, Arutha, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors in Cancer Therapy
por: Shiravand, Yavar, et al.
Publicado: (2022)

Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer
por: Ladwa, Rahul, et al.
Publicado: (2020)

Short term ex-vivo expansion of circulating head and neck tumour cells
por: Kulasinghe, Arutha, et al.
Publicado: (2016)

Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)
por: Singh, Charu
Publicado: (2014)

Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
por: Zhou, Yongchun, et al.
Publicado: (2017)

The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC)
por: Ramadhan, Hanan H, et al.
Publicado: (2021)

Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH
por: Swiatnicki, Matthew R., et al.
Publicado: (2022)

Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)
por: Makhov, Petr, et al.
Publicado: (2021)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
por: Zwitter, Matjaz, et al.
Publicado: (2016)

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
por: Kobayashi, Kunihiko, et al.
Publicado: (2013)

Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer
por: Ryan, Sarah-Louise, et al.
Publicado: (2021)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
por: Wu, Zhen, et al.
Publicado: (2019)

The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer
por: Burgess, Joshua T., et al.
Publicado: (2020)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
por: Hackner, Klaus, et al.
Publicado: (2021)

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC
por: MacDonagh, Lauren, et al.
Publicado: (2017)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

Heterogeneous distribution of EGFR mutation in NSCLC: Case report
por: Boukansa, Sara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2hadqaf6nm4gvo47t5aagc7t1f